Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Vericel Corproation (VCEL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 796,411
  • Shares Outstanding, K 43,807
  • Annual Sales, $ 90,860 K
  • Annual Income, $ -8,140 K
  • 60-Month Beta 3.04
  • Price/Sales 9.32
  • Price/Cash Flow N/A
  • Price/Book 8.20

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.06
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.07
  • Prior Year -0.15
  • Growth Rate Est. (year over year) +60.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.20 +12.22%
on 02/26/19
21.00 -13.45%
on 02/26/19
-1.39 (-7.10%)
since 02/22/19
3-Month
14.00 +29.86%
on 12/24/18
21.00 -13.45%
on 02/26/19
+3.84 (+26.78%)
since 12/21/18
52-Week
8.95 +103.13%
on 07/13/18
21.00 -13.45%
on 02/26/19
+7.58 (+71.51%)
since 03/22/18

Most Recent Stories

More News
What Makes Vericel (VCEL) a New Buy Stock

Vericel (VCEL) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

VCEL : 18.18 (-5.95%)
Vericel to Present at Multiple Upcoming Investor Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced presentations at multiple upcoming investor conferences.

VCEL : 18.18 (-5.95%)
Vericel (VCEL) Tops on Q4 Earnings & Sales, Stock Up

Vericel (VCEL) beat estimates for earnings as well as revenues in fourth-quarter 2018. Shares up in pre-market trading.

VCEL : 18.18 (-5.95%)
Vericel Reports Fourth Quarter and Full-Year 2018 Financial Results and Provides Full-Year 2019 Financial Guidance

Record Quarterly Product Revenues of $31.3 Million Represent a 41% Increase Over Fourth Quarter 2017

VCEL : 18.18 (-5.95%)
What's in Store for Vericel (VCEL) This Earnings Season?

On Vericel's (VCEL) fourth-quarter conference call, investor focus will be on the sales figures of the company's two approved medicines -- MACI and Epicel.

CARA : 18.30 (-6.82%)
BDSI : 5.11 (-3.58%)
VCEL : 18.18 (-5.95%)
ADRO : 3.67 (-5.17%)
Vericel to Participate in Multiple Upcoming Investor Conferences

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced participation in multiple upcoming investor conferences.

VCEL : 18.18 (-5.95%)
Vericel to Report Fourth-Quarter 2018 Financial Results on February 26, 2019

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the following webcast and conference call to discuss its fourth-quarter...

VCEL : 18.18 (-5.95%)
Vericel to Present at the 21st Annual Needham Growth Conference

Vericel Corporation (NASDAQ:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that Nick Colangelo, president and CEO, will present the latest...

VCEL : 18.18 (-5.95%)
Bull or Bear: Your Investment Strategy for 2019

Whether you're a bull or a bear, it may be a good idea to go defensive about now.

SCS : 14.77 (-3.46%)
VCTR : 14.76 (-3.53%)
INTT : 7.00 (-0.99%)
MMI : 37.91 (-2.92%)
III : 3.73 (+3.04%)
TIVO : 8.99 (-4.46%)
BEAT : 64.07 (-6.41%)
BMA : 46.47 (-9.10%)
DIOD : 35.97 (-4.66%)
PGR : 72.78 (-0.48%)
CPSI : 29.84 (-1.03%)
VCEL : 18.18 (-5.95%)
BHC : 24.69 (-3.06%)
VNDA : 17.59 (-4.61%)
Vericel Reports Publication of Outcomes Data From 954 Burn Patients Treated With Epicel in the Journal of Burn Care and Research

Vericel Corporation (Nasdaq:VCEL), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced the publication of outcomes data for 954 burn patients treated...

VCEL : 18.18 (-5.95%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade VCEL with:

Business Summary

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the...

See More

Key Turning Points

2nd Resistance Point 19.64
1st Resistance Point 18.91
Last Price 18.18
1st Support Level 17.77
2nd Support Level 17.36

See More

52-Week High 21.00
Last Price 18.18
Fibonacci 61.8% 16.40
Fibonacci 50% 14.98
Fibonacci 38.2% 13.56
52-Week Low 8.95

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar